Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas PharmaALPMF 77 Debt-to-EBITDA is 1.40 as of Mar. 2026, which is 35% below its 10-year median of 2.16. GuruFocus rates ALPMF with a GF Score™ of 77/100 and a GF Value™ of $14.19 (Fairly Valued). The stock has 4 warning signs investors should review. Among 690 Drug Manufacturers companies, Astellas Pharma ranks better than 62.61% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Astellas Pharma's Debt-to-EBITDA or its related term are showing as below:
ALPMF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.51 Med: 2.16 Max: 4.72
Current: 0.97
During the past 13 years, the highest Debt-to-EBITDA Ratio of Astellas Pharma was 4.72. The lowest was 0.51. And the median was 2.16.
ALPMF's Debt-to-EBITDA is ranked better than 62.61% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs ALPMF: 0.97
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Astellas Pharma Debt-to-EBITDA Related Terms
Astellas Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPMF vs LLY, JNJ, ABBV: Debt-to-EBITDA Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Astellas Pharma (ALPMF) has a Debt-to-EBITDA of 1.40 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Astellas Pharma. This is 35% below median its historical median of 2.16. Over the past decade, Astellas Pharma's Debt-to-EBITDA has ranged from 0.51 to 4.72. According to the industry distribution chart, Astellas Pharma ranks #258 out of 690 companies in the Drug Manufacturers industry, placing it in the top 37.4%.
Is Astellas Pharma's Debt-to-EBITDA too high?
Astellas Pharma's current Debt-to-EBITDA of 1.40 is 35% below median its 10-year median of 2.16. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 4.72. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Astellas Pharma's value of 1.40 is 16.7% below this industry median. Based on the distribution chart, Astellas Pharma ranks #258 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Debt-to-EBITDA compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #258 out of 690 companies for Debt-to-EBITDA. This puts Astellas Pharma in the upper half of its industry. The industry median Debt-to-EBITDA is 1.68. Astellas Pharma's value of 1.40 is 16.7% below this benchmark. Historically, Astellas Pharma's own Debt-to-EBITDA has ranged from 0.51 to 4.72 over the past decade. While the company's 10-year median is 2.16 vs. the industry median of 1.68, Astellas Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current Debt-to-EBITDA of 1.40 is 16.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Astellas Pharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current Debt-to-EBITDA is 1.40, which is 35% below median its own 10-year median of 2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.19, compared to a current price of $12.85 — trading 9.4% below its estimated fair value. The current Debt-to-EBITDA is 1.40, which is 35% below median its 10-year median of 2.16 and 16.7% below the Drug Manufacturers industry median of 1.68. Astellas Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Debt-to-EBITDA is 1.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $12.85 is trading 9.4% below its estimated GF Value™ of $14.19.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Debt-to-EBITDA: 1.40 (35% below median its 10-year median of 2.16)
GF Value™: $14.19 vs. price of $12.85 (9.4% below fair value)
Industry Position: 16.7% below the Drug Manufacturers median (#258 of 690)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
77GF Score
Get the complete analysis for ALPMF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
